RxDoctor Payments Data

Sarah Canyon, MD

Family Medicine · Kailua, HINPI 1588082259

Payments from drug & device makers

$583in general payments, 2019–2025

Across 14 payments — averaging $41.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$164
  • AbbVie$154
  • Lilly USA, LLC$100
  • Abbott$88
  • Exeltis, USA Inc.$24
  • Amarin Pharma, Inc.$21
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$583 in reported general payments places this provider in the 65th percentile of 376 family medicine providers in Hawaii.

See all family medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$86,399
Medicare patients
122
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin17$24,887
MounjaroTirzepatide15$17,101
OzempicSemaglutide12$11,433
Atorvastatin Calcium153$3,709
Ezetimibe19$1,351
Rosuvastatin Calcium31$1,152
SynthroidLevothyroxine Sodium17$1,113
Losartan Potassium87$1,003
Omeprazole36$910
Lisinopril58$887
Amlodipine Besylate97$858
Metoprolol Succinate45$682
Montelukast Sodium15$661
Duloxetine Hcl19$656
Famotidine25$656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$100$17,10115 claims
Novo NordiskOzempic$164$11,43312 claims
AbbVieSynthroid$154$1,11317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 376 family medicine providers in Hawaii.

Other family medicine in Kailua

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →